Thesan Pharmaceuticals, Inc. is a preclinical biopharmaceutical company dedicated to the development of novel therapeutics for disorders of the skin. Until recently, there has been comparatively limited innovation in the field of dermatology, where many companies have focused on the reformulation of existing drugs often resulting in marginal patient benefit. In contrast, Thesan is focused on the discovery and development of New Chemical Entities that have the potential to provide significantly improved treatment options to patients.
Our lead drug candidate is a first-in-class molecule with a novel mechanism of action. Initial target indications include atopic dermatitis (AD). The prevalence of AD has tripled in the last 30 years and is now experienced by at least 2% of adults and 20% of children in industrialized nations. Side effect that limit the utility of currently available treatment options include skin atrophy with topical steroids and a black box cancer warning with calcineurin inhibitors, the other major drug class used to treat AD patients.
Thesan Management has an expansive breadth of relevant sector experience having previously held executive positions in leading biopharmaceutical companies, and is backed by first tier investors: Novartis Venture Funds and Novo Ventures.